40, Dalton St

Boston,

MA,

USA,

ZIP: 02115

Phone: +16174554188

Through many years of neglect, the field of women's health has long been under researched and underfunded, resulting in the misdiagnosis and mistreatment of females across the world. From invasive diagnostic measures for endometriosis cases to outdated clinical techniques to determine an imbalance in vaginal microbiota, women have long felt under-represented across the health care system regarding indications of the reproductive system.

A combination of shared frustration and collaborative passion from industry pioneers has reignited the momentum across the field, shifting the investment spotlight to shine bright on women's health biotech and pharma. 2024 has already witnessed Freya Bioscience raising $38 million for microbial immunotherapies, as well as Heranova Lifesciences debuting $13.5 million in seed funding for clinical solutions across women's health. The time is now for the community to unite and drive clinical progress across women's health, paving the way for an increase in market access and hope for millions of women currently suffering across the globe.

The Women's Health Therapeutics and Diagnostics Summit presents the ultimate platform to combine forces across biotech and biopharma, showcasing the industry trailblazers to drive innovation and clinical progress across a range of disease indications. From endometriosis to bacterial vaginosis to infertility, pre-term birth, menopause and more, the need for in-depth conversations surrounding current standard of care, technological advancements and innovative pipeline developments has never been higher.

It is now imperative for industry to unite, with the likes of Ferring Pharmaceuticals, Organon, Hera Biotech, Evvy, Gynica, Freya Bioscience and more sharing case studies and data-driven insights, bringing the latest technological developments to the fore and overcoming the current translational challenges. A collective goal of propelling novel treatments and diagnostic tools to market in both a safe and efficacious manner remains pivotal, striving towards a personalized medicines approach.

Remain central to the conversation and hear from the world leaders in the field as 60+ women's health leads, clinical heads and experts from biotech and biopharma touch down in Boston to continue the revolution.

For more details about the program, speaker faculty or pricing and discounts, download the brochure.

URLs:
Brochure: https://go.evvnt.com/2341040-0?pid=1052
Tickets: https://go.evvnt.com/2341040-2?pid=1052

Prices:
Conference + 2 Workshops - Industry Pricing: USD 4197.00,
Conference + 1 Workshop - Industry Pricing: USD 3598.00,
Conference Only - Industry Pricing: USD 2999.00,
Conference + 2 Workshops - Discounted Pricing: USD 3597.00,
Conference + 1 Workshop - Discounted Pricing: USD 3098.00,
Conference Only - Discounted Pricing: USD 2599.00,
Conference + 2 Workshops - Vendor Pricing: USD 5097.00,
Conference + 1 Workshop - Vendor Pricing: USD 4398.00,
Conference Only - Vendor Pricing: USD 3699.00

Speakers: Shelley Amster, Co-Founder, Chief Strategy and Growth Officer, 3Daughters, Paul Korner, Chief Medical Officer, Agile Therapeutics, Jennifer Garrison, Assistant Professor, Buck Institute for Research on Aging, Stephen Palmer, Chief Scientific Officer, Celmatix, Jared Kehe,Co-founder and Chief Scientific Officer, Concerto Biociences, Roger Frechette, Chief Business Officer, Concerto Biociences, David Friend, Chief Scientific Officer, Dare Bioscience, Pita Navarro, Chief Scientific Officer, Evvy, Katie Barletta, Medical Director US RandD, Ferring Pharmaceuticals, Johan E.T. van Hylckama Vlieg, Chief Sceintific Officer and Co-Founder, Freya Biosciences, Yotam Hod, CEO and Co-Founder, Gynica, Cinzia Donato, Chief Operating Officer, Hera Biotech, Farideh Bischoff, Chief Medical Officer, Heranova Lifesciences, Natalie Getreu, Co-Founder and Chief Operating Officer, Hertility Health, Ridhi Tariyal, Chief Executive Officer and Co-Founder, Next Gen Jane, Edith Roset Bahmanyar, Executive Director Clinical Research, Organon, Denise Kelly, Investment Advisor, Seventure, Mark Connell, Chief Operating Officer, SLBST Pharma